Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd.

January 04, 2008 09:00 ET

Urodynamix Announces Grant of Stock Options

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 4, 2008) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) reported today that it has issued 145,000 incentive stock options to new employees of the Company. The stock options are being offered in conformance with TSX Venture Exchange regulations as incentive compensation and have a term of five years and an exercise price of $0.19 per share.

Urodynamix currently has outstanding 81,727,893 common shares and 6,863,500 incentive stock options. The company's Stock Option Plan allows the Board to issue the equivalent of up to 10% of the issued and outstanding share capital of the company on a rolling basis and was approved at the company's last Annual General Meeting held on June 4, 2007.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

On behalf of the Board,

Barry Allen, President & CEO

Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information